Abstract |
Recently, outcomes for patients with multiple myeloma have improved dramatically due to improved and innovative therapies. However, most patients will either relapse or become refractory to current therapy. Thus, a significant unmet need remains for novel agents to treat this patient population. Panobinostat, a potent pan-deacetylase inhibitor with a unique mechanism of action targeting both epigenetic regulation of gene expression and protein metabolism, has preclinical synergy with a number of agents, including the proteasome inhibitor bortezomib. In a phase 3 trial of panobinostat with bortezomib and dexamethasone, addition of panobinostat significantly prolonged the median progression-free survival of patients with relapsed or relapsed and refractory multiple myeloma. This review focuses on clinical development of panobinostat, with particular emphasis on pharmacokinetics and adverse event management.
|
Authors | Paul G Richardson, R Donald Harvey, Jacob P Laubach, Philippe Moreau, Sagar Lonial, Jesús F San-Miguel |
Journal | Expert review of clinical pharmacology
(Expert Rev Clin Pharmacol)
Vol. 9
Issue 1
Pg. 35-48
( 2016)
ISSN: 1751-2441 [Electronic] England |
PMID | 26503877
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents
- Histone Deacetylase Inhibitors
- Hydroxamic Acids
- Indoles
- Panobinostat
|
Topics |
- Antineoplastic Agents
(adverse effects, pharmacology, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, pharmacology, therapeutic use)
- Disease-Free Survival
- Epigenesis, Genetic
- Histone Deacetylase Inhibitors
(adverse effects, pharmacology, therapeutic use)
- Humans
- Hydroxamic Acids
(adverse effects, pharmacology, therapeutic use)
- Indoles
(adverse effects, pharmacology, therapeutic use)
- Multiple Myeloma
(drug therapy, pathology)
- Panobinostat
- Recurrence
|